Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?
Open Access
- 15 October 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4732
Abstract
Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outweigh their benefits. Another option, the implantable cardioverter defibrillator, though clearly the primary therapy for patients at high risk of ventricular arrhythmias, is costly, invasive, and requires regular monitoring. Thus there is a clear need for new antiarrhythmic treatment strategies. Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options. In this review we discuss emerging data from experimental studies that indicate new mechanism of action of this drug and further areas of investigation and potential use of ivabradine as an antiarrhythmic agent. However, clinical evidence is limited, and the jury is still out on effects of ivabradine on cardiac ventricular arrhythmias in the clinical setting.Keywords
This publication has 93 references indexed in Scilit:
- Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia–reperfusion-induced ventricular arrhythmiasJournal of Molecular and Cellular Cardiology, 2013
- Increased Expression of HCN Channels in the Ventricular Myocardium Contributes to Enhanced Arrhythmicity in Mouse Failing HeartsJournal of the American Heart Association, 2013
- Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot studyEuropean Heart Journal: Acute Cardiovascular Care, 2013
- Identification of the Molecular Site of Ivabradine Binding to HCN4 ChannelsPLOS ONE, 2013
- Novel blockers of hyperpolarization‐activated current with isoform selectivity in recombinant cells and native tissueBritish Journal of Pharmacology, 2011
- Long‐term treatment with ivabradine in post‐myocardial infarcted rats counteracts f‐channel overexpressionBritish Journal of Pharmacology, 2011
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s PacemakerCirculation Research, 2010
- Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expressionEuropean Heart Journal, 2009
- Transcription profiling of HCN-channel isotypes throughout mouse cardiac developmentBasic Research in Cardiology, 2009
- The Funny CurrentDrugs, 2007